Table 2.

Parasitological and clinical outcomes in therapeutic efficacy studies to evaluate artemether-lumefantrine or artesunate + sulfadoxine-pyrimethamine in Sudan (2010–2015)

	Site	Study years	N	PD3	PCR un-corrected					PCR corrected
					Excl/loss	ETF	LCF	LPF	ACPR	Excl/loss	ETF	LCF	LPF	ACPR	Cure rate (KM)	(95 % CI)
AS + SP	Kosti	2010	92	0	6	0	4	0	82	6	0	4	0	82	95.3	(88.1–98.2)
	Sennar	2010	97	0	5	0	4	1	87	6	0	3	1	87	95.7	(89.0–98.4)
	Gedaref	2011-12	100	0	0	0	3	10	87	4	0	3	6	87	91	(83.4–95.2)
	Kassala	2011	75	0	1	0	2	1	71	3	0	1	0	71	98.6	(90.7–99.8)
	Kosti	2011	98	0	8	0	5	0	85	13	0	0	0	85	100	(95.8–100)
	Sennara	2011	95	0	1	0	6	7	81	12	0	0	1	81	98.9	(92.5–99.8)
	Kostia	2012-13	95	0	7	0	1	4	83	11	0	0	0	83	100	(95.7–100)
	Damazina	2013-14	100	0	26	0	3	5	66	30	0	1	2	66	95.9	(87.9–98.7)
	Sennnar	2013-14	88	0	0	0	2	6	80	5	0	1	2	80	96.4	(89.2–98.8)
	New Halfa	2013-14	80	0	0	1	0	0	79	0	1	0	0	79	98.7	(91.4–99.8)
	Gedarefa	2014-15	93	1	0	0	7	15	70	10	0	2	10	70	86.5	(77.5–92.1)
AL	Damazin	2010	67	0	0	1	0	0	66	0	1	0	0	66	98.5	(89.9–99.8)
	Kassala	2010	85	0	1	0	0	0	84	1	0	0	0	84	100	(95.7–100)
	Kosti	2012-13	101	0	10	0	1	1	89	12	0	0	0	89	100	(95.9–100)
	Damazin	2013	98	0	12	0	1	6	79	18	0	0	1	79	98.9	(92.1–99.8)
	Kassalaa	2013-14	84	0	1	0	1	0	82	1	0	0	0	82	100	(95.6–100)
	Sennar-Almazad	2013-14	42	0	11	0	0	2	29	12	0	0	1	29	96.8	(79.2–99.5)
	Gedaref-Rawashda	2013-14	35	0	0	0	0	0	35	0	0	0	0	35	100	n/a
	Sennar-Abei	2014	41	0	0	0	1	1	39	1	0	1	0	39	97.5	(83.5–99.6)
	Gedaref-Karari	2014-15	42	1	0	0	0	1	41	0	0	0	1	41	97.7	(84.3–99.7)

PD3 positive on day 3, LCF late clinical failure, LPF late parasitological failure, ACPR adequate clinical and parasitological response, KM Kaplan–Meier, CI confidence interval

^aIn the PCR-corrected analysis, one patient was excluded, due to unknown PCR in AS + SP studies in Sennar (2011), Kosti (2012–13), Damazin (2013–14), Gedaref (2014–15) and in AL Kassala study of 2013–14